Xu Dan, Zhu Hong, Wu Meng
Department of Oral and Maxillofacial Surgery, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, 223300, Jiangsu Province, China.
Department of Pharmacy, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, 223300, Jiangsu Province, China.
Heliyon. 2024 Sep 26;10(19):e38561. doi: 10.1016/j.heliyon.2024.e38561. eCollection 2024 Oct 15.
Drug-induced dry mouth is an adverse reaction that can significantly affect the quality of life and mental state of patients. In this study, we aimed to identify the most common drugs associated with dry mouth using data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database.
We accessed data from the FAERS database between the first quarter of 2004 and the first quarter of 2024. The Medical Dictionary for Regulatory Activities was used to identify reports of dry mouth, and disproportionality analyses (reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker) were performed to examine the risk signals for dry mouth and its causative drugs.
A total of 75,899 adverse event reports were related to dry mouth. Tiotropium bromide monohydrate (2080 cases) was associated with the majority of dry mouth cases. Disproportionality analysis revealed that the top five drugs with the highest reporting odds ratio (ROR) were darifenacin, solifenacin succinate, fesoterodine fumarate, tolterodine tartrate, and niraparib. Moreover, eight of the top 19 drugs that caused dry mouth were not identified as having major side effects in the package inserts.
Tiotropium bromide monohydrate was the most frequently reported drug for dry mouth, whereas darifenacin had the highest ROR. Collectively, our findings emphasize the necessity for improved recognition and management of drug-induced dry mouth, particularly for medications not adequately flagged for this side effect in their labels.
药物性口干是一种不良反应,会显著影响患者的生活质量和精神状态。在本研究中,我们旨在利用美国食品药品监督管理局不良事件报告系统(FAERS)数据库的数据,确定与口干相关的最常见药物。
我们获取了2004年第一季度至2024年第一季度FAERS数据库的数据。使用《监管活动医学词典》识别口干报告,并进行不成比例分析(报告比值比、比例报告比、贝叶斯置信传播神经网络和多项目伽马泊松收缩器),以检查口干及其致病药物的风险信号。
共有75899份不良事件报告与口干有关。一水合噻托溴铵(2080例)与大多数口干病例相关。不成比例分析显示,报告比值比(ROR)最高的前五种药物是达非那新、琥珀酸索利那新、富马酸非索罗定、酒石酸托特罗定和尼拉帕利。此外,导致口干的前19种药物中有8种在药品说明书中未被确定为有主要副作用。
一水合噻托溴铵是报告中最常导致口干的药物,而达非那新的ROR最高。总体而言,我们的研究结果强调了改善对药物性口干的认识和管理的必要性,特别是对于那些在标签中未充分标明这种副作用的药物。